cardiomyopathy (DCM), and Duchenne-associated cardiomyopathy. The company’s lead therapeutic candidate, STM-01, is being evaluated in clinical trials, while additional programs such as STM-21 are in preclinical development for inflammatory and tissue repair applications. Secretome Therapeutics uses neonatal cardiac tissue obtained during medically necessary surgeries to develop cell-based and secretome-based therapies intended to support tissue repair and reduce inflammation. The company’s platform is designed to produce scalable and consistent therapies by using neonatal-derived cells that demonstrate lower variability compared to adult-derived stem cells.